Biden Inauguration


We have NEW internet #telekom DSL replacing our #Vodafone cable. Thank baby Jesus. Vodafone needs to rethink what they are offering to their clients. It's a total scam.
We've been paying for 50 upload for months be only get between 1-3 for over 5 weeks now, everyday documented with a speed test.
We'll let's see how the first stream goes with the new internet. See you guys at 9am EST!



Live Stream

Timestamps in video description


Research / Recap / Additional Video

I bought VIH yesterday @ 14.92, yes yes, another SPAC.. BUT it's not an EV SPAC lol it's the company that will be taking BAKKT public! This is the exchange that many of the big players use to invest into crypto. So if you guys also want additional crypto exposure this is an interesting play via equites.

Recent Motely Fool article for some further reading:

Former CEO Kelly Loeffler

The fool article isn't too good but this one is quite a nice update, especially on Kelly:

Good VW article here if you guys have time

"The biggest challenge, said Mr. Hilgenberg, isn’t the technology, it is the mind-set of the people—their reluctance to embrace radical change until circumstances force them to."

“Over the past 20 years the auto industry became more integrators than developers,” said Mr. Hitzinger. “Software is written by suppliers. This was good for a while because it drives down costs but you lose control. That’s what the auto industry has to reverse now, bring in deep technical knowledge. That’s the hard part.”

Change is coming, Mr. Diess wrote on his LinkedIn page, and VW must move faster. “The global transformation of the industry will take roughly 10 years,” he wrote. “With or without Volkswagen.”


YxngMoeโ€‹this is onlycleanbangerz just changed my name lol


BTWN Bridgetown holdings

426dfvโ€‹Alex: backed by billionaires Richard Li and Peter Thiel



Inuvo, Inc.
Communication Services | Advertising Agencies | USA

46% 66mc 88f

No New News..

Jan-14-21 08:30AM  


ENDRA Life Sciences Inc.
Healthcare | Diagnostics & Research | USA

46% 34mc 23f

No New News..

Jan-13-21 09:00AM  
Jan-08-21 09:00AM  


Dare Bioscience, Inc.
Healthcare | Biotechnology | USA

23% 105mc 35f

jan 19th "Not seeing any company specific news"

Jan-05-21 08:00AM  


Steel Connect, Inc.
Industrials | Integrated Freight & Logistics | USA

70% 92mc 56f

No new news?

Jan-11-21 08:00AM  
Jan-08-21 04:15PM  


AutoWeb, Inc.
Communication Services | Internet Content & Information | USA

60% 42mc 10f

No new news?

Dec-17-20 08:00AM  
Nov-26-20 11:36PM  


Caladrius Biosciences, Inc.
Healthcare | Biotechnology | USA

130% 32mc 17f

"We are very excited about our CLBS16 program as it represents a potential breakthrough in the treatment of CMD, a condition which afflicts millions of patients in the US alone, many of whom are women. As a result, CMD is a women's health issue of emerging importance as currently there are no products with approved labeling for coronary microvascular dysfunction," said David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius. "The treatment of the first patient in the FREEDOM trial is an important milestone for our Company and the program and we look forward to completing enrollment by the target of year-end 2021. It is especially noteworthy that even during the COVID-19 pandemic, physicians and patients are active in our trial, denoting the seriousness of the disease and underscoring the lack of available effective treatment for CMD."

Jan-19-21 08:00AM  
Jan-06-21 08:30AM  


Aptorum Group Limited
Healthcare | Biotechnology | United Kingdom

70% 93mc 9f

Jan 20th - Aptorum Group Limited (NASDAQ:APM, Euronext Paris: APM))))) ) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced that the company, through its wholly owned subsidiary, Aptorum International Limited, has received clearance from the Public Health Agency of Canada (Health Canada) regarding the Clinical Trial Application (CTA) to commence a Phase 1 study of ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA.

Jan-20-21 06:00AM  
Jan-16-21 01:23AM  


Obalon Therapeutics, Inc.
Healthcare | Medical Devices | USA

65% 14mc 8f

January 20, 2021 08:42 AM ET (BZ Newswire) -- M&A

Merger Agreement

On January 19, 2021, Obalon Therapeutics, Inc., a Delaware corporation (“Obalon”), Optimus Merger Sub, Inc., a Delaware corporation, and a direct, wholly owned subsidiary of Obalon (“Merger Sub”), and ReShape Lifesciences, Inc., a Delaware corporation (“ReShape”), entered into an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, Merger Sub shall be merged with and into ReShape, with ReShape surviving as a wholly owned subsidiary of Obalon. Capitalized terms used herein but not defined shall have the respective meanings assigned to them in the Merger Agreement.





Free Gap Scanner + Win 2 Free Stocks ๐ŸŽ‰ (Each Up To $1600) ๐Ÿ‘‰๐Ÿ‘‰

Best Savings Account Ever! ๐Ÿ˜ Win $10 Million - Use Code: WINKLER ๐Ÿ‘‰๐Ÿ‘‰

Watchlist ๐Ÿ‘‰๐Ÿ‘‰